Revance Therapeutics (RVNC) Tops Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Revance Therapeutics (RVNC) Tops Q4 EPS by 3c

Revance Theraputics (RVNC) Pipeline is Underappreciated - Guggenheim

March 3, 2016 9:05 AM EST

Guggenheim analyst, Louise Chen, believes Revance Therapeutics' (NASDAQ: RVNC) pipeline prospects are underappreciated. She expects five launches over five years beginning in '19 that should drive upward earnings revisions and multiple expansion to levels not reflected in consensus expectations. No change to Buy rating or $55 PT.

The launches include:

1) RT001, topical for Crows Feet Lines in '19

2) RT002, injectable for glabellar... More